Research ExplorerPublicationsChildhood medulloblastoma.

Childhood medulloblastoma.

Standard

Childhood medulloblastoma. / Massimino, Maura; Giangaspero, Felice; Garrè, Maria Luisa; Gandola, Lorenza; Poggi, Geraldina; Biassoni, Veronica; Gatta, Gemma; Rutkowski, Stefan.

In: CRIT REV ONCOL HEMAT, Vol. 79, No. 41, 41, 2011, p. 65-83.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Massimino, M, Giangaspero, F, Garrè, ML, Gandola, L, Poggi, G, Biassoni, V, Gatta, G & Rutkowski, S 2011, 'Childhood medulloblastoma.', CRIT REV ONCOL HEMAT, vol. 79, no. 41, 41, pp. 65-83. <http://www.ncbi.nlm.nih.gov/pubmed/21129995?dopt=Citation>

APA

Massimino, M., Giangaspero, F., Garrè, M. L., Gandola, L., Poggi, G., Biassoni, V., Gatta, G., & Rutkowski, S. (2011). Childhood medulloblastoma. CRIT REV ONCOL HEMAT, 79(41), 65-83. [41]. http://www.ncbi.nlm.nih.gov/pubmed/21129995?dopt=Citation

Vancouver

Massimino M, Giangaspero F, Garrè ML, Gandola L, Poggi G, Biassoni V et al. Childhood medulloblastoma. CRIT REV ONCOL HEMAT. 2011;79(41):65-83. 41.

Bibtex

@article{ee6edf10b5454351901641138a3d7170,
title = "Childhood medulloblastoma.",
abstract = "Among all the childhood central nervous system tumours, medulloblastoma and other neuroectodermal tumours account for 16-25% of cases. The causative factors of medulloblastoma/PNET have not been well established. It is more frequent in boys than in girl and in children than in adults. There was a significant improvement of survival for children diagnosed in 2000-2002 compared to those diagnosed in 1995-1999. The risk of dying was reduced by 30%. Patients are generally divided into risk-stratified schemes on the basis of age, the extent of residual disease, and dissemination. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those in the disseminated category, and in North American trials those that have less than a gross or near-total resection, which is arbitrarily defined as 1.5cm(2) of post-operative residual disease. Current and currently planned clinical trials will:define molecular and biological markers that improve outcome prediction in patients with medulloblastoma and which can be incorporated for front-line stratification of newly defined risk subgroups.",
author = "Maura Massimino and Felice Giangaspero and Garr{\`e}, {Maria Luisa} and Lorenza Gandola and Geraldina Poggi and Veronica Biassoni and Gemma Gatta and Stefan Rutkowski",
year = "2011",
language = "Deutsch",
volume = "79",
pages = "65--83",
journal = "CRIT REV ONCOL HEMAT",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "41",

}

RIS

TY - JOUR

T1 - Childhood medulloblastoma.

AU - Massimino, Maura

AU - Giangaspero, Felice

AU - Garrè, Maria Luisa

AU - Gandola, Lorenza

AU - Poggi, Geraldina

AU - Biassoni, Veronica

AU - Gatta, Gemma

AU - Rutkowski, Stefan

PY - 2011

Y1 - 2011

N2 - Among all the childhood central nervous system tumours, medulloblastoma and other neuroectodermal tumours account for 16-25% of cases. The causative factors of medulloblastoma/PNET have not been well established. It is more frequent in boys than in girl and in children than in adults. There was a significant improvement of survival for children diagnosed in 2000-2002 compared to those diagnosed in 1995-1999. The risk of dying was reduced by 30%. Patients are generally divided into risk-stratified schemes on the basis of age, the extent of residual disease, and dissemination. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those in the disseminated category, and in North American trials those that have less than a gross or near-total resection, which is arbitrarily defined as 1.5cm(2) of post-operative residual disease. Current and currently planned clinical trials will:define molecular and biological markers that improve outcome prediction in patients with medulloblastoma and which can be incorporated for front-line stratification of newly defined risk subgroups.

AB - Among all the childhood central nervous system tumours, medulloblastoma and other neuroectodermal tumours account for 16-25% of cases. The causative factors of medulloblastoma/PNET have not been well established. It is more frequent in boys than in girl and in children than in adults. There was a significant improvement of survival for children diagnosed in 2000-2002 compared to those diagnosed in 1995-1999. The risk of dying was reduced by 30%. Patients are generally divided into risk-stratified schemes on the basis of age, the extent of residual disease, and dissemination. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those in the disseminated category, and in North American trials those that have less than a gross or near-total resection, which is arbitrarily defined as 1.5cm(2) of post-operative residual disease. Current and currently planned clinical trials will:define molecular and biological markers that improve outcome prediction in patients with medulloblastoma and which can be incorporated for front-line stratification of newly defined risk subgroups.

M3 - SCORING: Zeitschriftenaufsatz

VL - 79

SP - 65

EP - 83

JO - CRIT REV ONCOL HEMAT

JF - CRIT REV ONCOL HEMAT

SN - 1040-8428

IS - 41

M1 - 41

ER -